Anbio Biotechnology, a Germany-based developer of in vitro diagnostics products, filed on Tuesday with the SEC to raise up to $9 million in an initial public offering.
The Frankfurt am Main, Germany-based company plans to raise $9 million by offering 1.6 million shares at a price range of $5 to $6.
Anbio Biotechnology develops an array of in vitro diagnostics products for OTC utilization, point-of-care settings, and laboratory applications. Its products are designed for an array of conditions, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes.
The Frankfurt am Main, Germany-based company was founded in 2021 and plans to list on the Nasdaq under the symbol NNNN. AC Sunshine Securities is the sole bookrunner on the deal.
